Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

NCT05780905 on ClinicalTrials.gov · last registry update 2024-06-05

Recruiting now, toward 50 participants. Its estimated completion date, 31 March 2026, has passed with no update to the record. Primary outcome, as filed: Intracranial blood flow (IBF). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Washington
Sponsor type: Other
Enrollment: 50
Started: 2024-01-11
Primary completion: 2026-03-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Intracranial blood flow (IBF)

Conditions studied

Diabetes Mellitus, Type 2 · Stroke (CVA) or Transient Ischemic Attack

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.